Tango Therapeutics, Inc. (TNGX) Financials
TNGX Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 402.6 million | 149.5 million |
2023-09-30 | 428.2 million | 151.6 million |
2023-06-30 | 379.3 million | 166.4 million |
2023-03-31 | 403.8 million | 176.5 million |
TNGX Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | -27.7 million | 4.9 million |
2023-09-30 | -31.2 million | 4.9 million |
2023-06-30 | -25.1 million | 5.1 million |
2023-03-31 | -35.5 million | 4.2 million |
TNGX Net Income
No data available :(
TNGX Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 336.9 million | - | 38.9 million |
2023-09-30 | 359.9 million | - | 39.5 million |
2023-06-30 | 310.7 million | - | 39.9 million |
2023-03-31 | 333.6 million | - | 41.4 million |
TNGX Shares Outstanding
TNGX Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 226000 | 31.3 million | 9.1 million | - |
2023-09-30 | 16000 | 27.1 million | 9.2 million | - |
2023-06-30 | 664000 | 28.7 million | 9.2 million | - |
2023-03-31 | 620000 | 28.0 million | 8.0 million | - |
TNGX Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 5.4 million | 617000 |
2023-09-30 | 10.7 million | 613000 |
2023-06-30 | 14.6 million | 1.5 million |
2023-03-31 | 5.8 million | 1.5 million |
TNGX
Price: $7.44
52 week price:
Earnings Per Share: -1.08 USD
P/E Ratio: -11.60
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 179400
Market Capitalization: 784.4 million